Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Reactions Weekly
Published in: Reactions Weekly 1/2023

01-08-2023 | Ustekinumab | Case report

Ustekinumab

Hodgkin's lymphoma: case report

Published in: Reactions Weekly | Issue 1/2023

Login to get access

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
…
Literature
Yanai H, et al. Endoscopic Postoperative Recurrence in Crohn's Disease After Curative Ileocecal Resection with Early Prophylaxis by Anti-TNF, Vedolizumab or Ustekinumab: A Real-World Multicentre European Study. Journal of Crohn's and Colitis 16: 1882-1892, No. 12, et al. Dec 2022. Available from: URL: http://​doi.​org/​10.​1093/​ecco-jcc/​jjac100
Metadata
Title
Ustekinumab
Hodgkin's lymphoma: case report
Publication date
01-08-2023
Publisher
Springer International Publishing
Published in
Reactions Weekly / Issue 1/2023
Print ISSN: 0114-9954
Electronic ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-023-45114-4

Other articles of this Issue 1/2023

Reactions Weekly 1/2023 Go to the issue

Case report

Progesterone

Case report

Citalopram

Case report

Ketamine

Case report

Multiple drugs

Case report

Docetaxel/pertuzumab/trastuzumab

Case report

Capecitabine